|
|
|
|
|
|
|
|
|
09.03.26 - 10:30
|
HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China (GlobeNewswire EN)
|
|
|
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces an update regarding TAZVERIK® (tazemetostat), an oncology therapy licensed from Epizyme, Inc. (“Epizyme”), an Ipsen (“Ipsen”) company, in China. Epizyme is the Marketing Authorization Holder of TAZVERIK® in the Chinese mainland, for which HUTCHMED Limited (a subsidiary of the Company) acts as the domestic agent/licensee. Ipsen has informed HUTCHMED that it is voluntarily withdrawing TAZVERIK® in the US. As a result, steps have been taken to initiate the market withdrawal and product recall in China. Consequently, HUTCHMED Limited has initiated a withdrawal and product recall from the Chinese mainland, Hong Kong and Macau, and is discontinuing all active tazemetostat clinical trials. Existing patients should consult their treating physicians immediately to discuss their treatment options....
|
|
|
09.03.26 - 05:30
|
Research: CLSA Cuts TP of HUTCHMED to HKD30.4; Rating Outperform (AAStocks)
|
|
|
CLSA published a research report on HUTCHMED (00013.HK), which delivered mixed results for 2025, with sales figures falling short of forecast in light of commercial headwinds, while net profit exceeded expectations. The broker indicated that the 2026 oncology business guidance suggests an impending commercial recovery, and the n......
|
|
|
06.03.26 - 09:33
|
Intended Retirement of Independent Non-executive Director and changes of composition of board committees (GlobeNewswire EN)
|
|
|
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces that Professor Mok Shu Kam, Tony has informed the Company that he would not seek re-election after retiring from the Board at the forthcoming annual general meeting of the Company to be held on May 12, 2026 (“AGM”). Professor Mok has served as an Independent Non-executive Director of the Company for more than eight years, approaching the nine-year cap on the tenure of independent non-executive directors under the Hong Kong Listing Rules. Consequently, he will cease to be an Independent Non-executive Director of the Company at the conclusion of the AGM. Upon his retirement, he will also step down from his roles as chairman and member of the board committees of the Company. ...
|
|
|
06.03.26 - 03:30
|
HUTCHMED Leaps 5%+ This Morning as 2025 Net Income Surges 11x (AAStocks)
|
|
|
HUTCHMED (00013.HK) opened 0.57% higher today and once peaked at HKD22.3. It last traded at HKD22.3, up 5.89%, with a volume of 1.282 million shares, involving HKD28.0713 million.The company announced its 2025 results yesterday. Its total revenue dropped by 13% YoY to USD549 million, while its net income grew by 11 times to USD4......
|
|
|
|
|
05.03.26 - 14:03
|
Hutchmed China Ltd. Full Year Profit Advances (AFX)
|
|
|
BEIJING (dpa-AFX) - Hutchmed China Ltd. (HCM) released earnings for its full year that Increased, from last yearThe company's earnings came in at $456.909 million, or $0.52 per share. This compare......
|
|
|
|
|
|
|
|
|
|
|
06.02.26 - 09:33
|
HUTCHMED to Announce 2025 Final Results (GlobeNewswire EN)
|
|
|
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Feb. 06, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2025 on Thursday, March 5, 2026 at 6:00 am Eastern Standard Time (EST) / 11:00 am Greenwich Mean Time (GMT) / 7:00 pm Hong Kong Time (HKT)....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
